UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Effect of budesonide/formoterol maintenance and reliever therapy on asthma exacerbations

International journal of clinical practice (Esher), 2007-05, Vol.61 (5), p.725-736

2007

Volltextzugriff (PDF)

Salbutamol use in relation to maintenance bronchodilator efficacy in COPD: a prospective subgroup analysis of the EMAX trial

Respiratory research, 2020-10, Vol.21 (1), p.280-280, Article 280

2020

Volltextzugriff (PDF)

Cost-effectiveness analysis of umeclidinium bromide/vilanterol 62.5/25 mcg versus tiotropium/olodaterol 5/5 mcg in symptomatic patients with chronic obstructive pulmonary disease: a Spanish National Healthcare System perspective

Respiratory research, 2018-11, Vol.19 (1), p.224-224, Article 224

2018

Volltextzugriff (PDF)

Correction to: Cost-effectiveness analysis of umeclidinium bromide/vilanterol 62.5/25 mcg versus tiotropium/olodaterol 5/5 mcg in symptomatic patients with chronic obstructive pulmonary disease: a Spanish National Healthcare System perspective

Respiratory research, 2019-01, Vol.20 (1), p.18-18, Article 18

2019

Volltextzugriff (PDF)

Budesonide/formoterol maintenance and reliever therapy: an effective asthma treatment option?

The European respiratory journal, 2005-11, Vol.26 (5), p.819-828

2005

Volltextzugriff (PDF)

Efficacy and safety of budesonide/formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthma

Current medical research and opinion, 2004-09, Vol.20 (9), p.1403-1418

2004

Volltextzugriff (PDF)

Long-term cost and utility consequences of short-term clinically important deterioration in patients with chronic obstructive pulmonary disease: results from the TORCH study

International journal of chronic obstructive pulmonary disease, 2019-05, Vol.14, p.939-951

2019

Volltextzugriff (PDF)

Budesonide/formoterol for maintenance and reliever therapy of asthma: a meta analysis of randomised controlled trials

International journal of clinical practice (Esher), 2010-04, Vol.64 (5), p.619-627

2010

Volltextzugriff (PDF)

Prevalence and burden of dyspnoea among COPD patients in Japan

International journal of clinical practice (Esher), 2016-08, Vol.70 (8), p.676-681

2016

Volltextzugriff (PDF)

Budesonide/Formoterol Maintenance and Reliever Therapy in Asian Patients (Aged ≥16 Years) with Asthma: A Sub-Analysis of the COSMOS Study

Clinical drug investigation, 2012-07, Vol.32 (7), p.439-449

2012

Volltextzugriff (PDF)

Treatment of COPD with Long-Acting Bronchodilators: Association Between Early and Longer-Term Clinically Important Improvement

International journal of chronic obstructive pulmonary disease, 2021-01, Vol.16, p.1215-1226

2021

Volltextzugriff (PDF)

S101 The impact of smoking on improving COPD outcomes with umeclidinium/vilanterol: a pre-specified analysis of the EMAX trial

Thorax, 2019-12, Vol.74 (Suppl 2), p.A63

2019

Volltextzugriff (PDF)

Impact of changes to reimbursement of fixed combinations of inhaled corticosteroids and long-acting β2-agonists in obstructive lung diseases: a population-based, observational study

International journal of clinical practice (Esher), 2014-07, Vol.68 (7), p.812-819

2014

Volltextzugriff (PDF)

Zafirlukast Improves Asthma Control in Patients Receiving High-Dose Inhaled Corticosteroids

American journal of respiratory and critical care medicine, 2000-08, Vol.162 (2), p.578-585

2000

Volltextzugriff (PDF)

Once-daily budesonide/formoterol in a single inhaler in adults with moderate persistent asthma

Respiratory medicine, 2003-04, Vol.97 (4), p.323-330

2003

Volltextzugriff (PDF)

Recent advances of artificial intelligence in melanoma clinical practice

Melanoma research, 2023-12, Vol.33 (6), p.454-461

2023

Volltextzugriff (PDF)

S57 Short-term clinically important deterioration predicts long-term clinical outcome in COPD patients: A post-hoc analysis of the TORCH trial

Thorax, 2015-12, Vol.70 (Suppl 3), p.A34-A35

2015

Volltextzugriff (PDF)

P122 Combination therapy with inhaled salmeterol plus fluticasone propionate is more effective than salmeterol alone in reducing the risk of clinically important deterioration in COPD: A post-hoc analysis of the TORCH trial

Thorax, 2015-12, Vol.70 (Suppl 3), p.A136

2015

Volltextzugriff (PDF)

P122 Combination therapy with inhaled salmeterol plus fluticasone propionate is more effective than salmeterol alone in reducing the risk of clinically important deterioration in COPD: A post-hoc analysis of the TORCH trial: Abstract P122 Table 1

Thorax, 2015-12, Vol.70 (Suppl 3), p.A136-A137

2015

Volltextzugriff (PDF)

Compliance with an oral asthma medication: a pilot study using an electronic monitoring device

Respiratory medicine, 2000-09, Vol.94 (9), p.852-858

2000

Volltextzugriff (PDF)

D36 COPD: LABA, LAMA, ICS, AND COMBINATIONS: Comparative Efficacy Of Umeclidinium With Other Once-Daily Long-Acting Muscarinic Antagonists In Moderate-To-Severe Chronic Obstructive Pulmonary Disease

American journal of respiratory and critical care medicine, 2016-01, Vol.193, p.1

2016

Volltextzugriff (PDF)

C41 LONG ACTING BRONCHODILATOR THERAPY IN COPD II: Integrated Safety Analysis Comparing Umeclidinium/vilanterol With Tiotropium

American journal of respiratory and critical care medicine, 2017-01, Vol.195

2017

Volltextzugriff (PDF)

Dual Bronchodilator Therapy as First-Line Treatment in Maintenance-Naïve Patients with Symptomatic COPD: A Pre-Specified Analysis of the EMAX Trial

International journal of chronic obstructive pulmonary disease, 2021-01, Vol.16, p.1939-1956

2021

Volltextzugriff (PDF)

Is Decoupling GDP Growth from Environmental Impact Possible?

PloS one, 2016-10, Vol.11 (10), p.e0164733-e0164733

2016

Volltextzugriff (PDF)

P275 Comparing clinically relevant improvement with umeclidinium/vilanterol and tiotropium/olodaterol in symptomatic copd: a randomised non-inferiority crossover trial

Thorax, 2017-12, Vol.72 (Suppl 3), p.A232

2017

Volltextzugriff (PDF)

1 – 25 von 4.189

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(2.927)
Mit Volltextzugriff
(3.267)

Publikationsform

4 weitere anzeigen...

Weniger anzeigen...

Sprache

8 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(1.878)
Life Sciences & Biomedicine
(1.049)
Humans
(675)
Technology
(500)
Male
(487)
Physical Sciences
(450)
Female
(377)
Middle Aged
(310)
Animals
(284)
Chemistry
(274)
Engineering
(274)
Aged
(236)
Biological And Medical Sciences
(236)
Computer Science
(225)
Adult
(221)
Medical Sciences
(175)
Engineering, Electrical & Electronic
(172)
Social Sciences
(148)
Science & Technology - Other Topics
(129)
Urology & Nephrology
(122)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

EZB Electronic Journals Library
(1.516)
Ingenta
(1.479)
MEDLINE
(935)
Access via ScienceDirect (Elsevier)
(610)
Journals@Ovid
(595)
IngentaConnect Journals
(513)
Single Online Journals
(471)
Springer journals
(368)
Wiley-Blackwell Journals
(347)
Ebook Central Perpetual and DDA
(314)
Elsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)
(309)
Wiley Online Library
(225)
IEEE Electronic Library Online
(222)
SpringerLINK Contemporary (Konsortium Baden-Württemberg)
(203)
De Gruyter eBooks
(170)
JSTOR All Journals
(159)
eBooks on EBSCOhost
(144)
Oxford journals
(111)
Taylor & Francis Online Single Subscriptions
(97)
Taylor & Francis Online
(96)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Effect of budesonide/formoterol maintenance and reliever therapy on asthma exacerbations

Salbutamol use in relation to maintenance bronchodilator efficacy in COPD: a prospective subgroup analysis of the EMAX trial

Cost-effectiveness analysis of umeclidinium bromide/vilanterol 62.5/25 mcg versus tiotropium/olodaterol 5/5 mcg in symptomatic patients with chronic obstructive pulmonary disease: a Spanish National Healthcare System perspective

Correction to: Cost-effectiveness analysis of umeclidinium bromide/vilanterol 62.5/25 mcg versus tiotropium/olodaterol 5/5 mcg in symptomatic patients with chronic obstructive pulmonary disease: a Spanish National Healthcare System perspective

Budesonide/formoterol maintenance and reliever therapy: an effective asthma treatment option?

Efficacy and safety of budesonide/formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthma

Long-term cost and utility consequences of short-term clinically important deterioration in patients with chronic obstructive pulmonary disease: results from the TORCH study

Budesonide/formoterol for maintenance and reliever therapy of asthma: a meta analysis of randomised controlled trials

Prevalence and burden of dyspnoea among COPD patients in Japan

Budesonide/Formoterol Maintenance and Reliever Therapy in Asian Patients (Aged ≥16 Years) with Asthma: A Sub-Analysis of the COSMOS Study

Treatment of COPD with Long-Acting Bronchodilators: Association Between Early and Longer-Term Clinically Important Improvement

S101 The impact of smoking on improving COPD outcomes with umeclidinium/vilanterol: a pre-specified analysis of the EMAX trial

Impact of changes to reimbursement of fixed combinations of inhaled corticosteroids and long-acting β2-agonists in obstructive lung diseases: a population-based, observational study

Zafirlukast Improves Asthma Control in Patients Receiving High-Dose Inhaled Corticosteroids

Once-daily budesonide/formoterol in a single inhaler in adults with moderate persistent asthma

Recent advances of artificial intelligence in melanoma clinical practice

S57 Short-term clinically important deterioration predicts long-term clinical outcome in COPD patients: A post-hoc analysis of the TORCH trial

P122 Combination therapy with inhaled salmeterol plus fluticasone propionate is more effective than salmeterol alone in reducing the risk of clinically important deterioration in COPD: A post-hoc analysis of the TORCH trial

P122 Combination therapy with inhaled salmeterol plus fluticasone propionate is more effective than salmeterol alone in reducing the risk of clinically important deterioration in COPD: A post-hoc analysis of the TORCH trial: Abstract P122 Table 1

Compliance with an oral asthma medication: a pilot study using an electronic monitoring device

D36 COPD: LABA, LAMA, ICS, AND COMBINATIONS: Comparative Efficacy Of Umeclidinium With Other Once-Daily Long-Acting Muscarinic Antagonists In Moderate-To-Severe Chronic Obstructive Pulmonary Disease

C41 LONG ACTING BRONCHODILATOR THERAPY IN COPD II: Integrated Safety Analysis Comparing Umeclidinium/vilanterol With Tiotropium

Dual Bronchodilator Therapy as First-Line Treatment in Maintenance-Naïve Patients with Symptomatic COPD: A Pre-Specified Analysis of the EMAX Trial

Is Decoupling GDP Growth from Environmental Impact Possible?

P275 Comparing clinically relevant improvement with umeclidinium/vilanterol and tiotropium/olodaterol in symptomatic copd: a randomised non-inferiority crossover trial

Suchergebnisse filtern